Examine the evolution of American Tower's (AMT) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.
Qure stock plunged 45% after FDA rejected AMT-130 approval pathway, requiring new randomized trial for Huntington's disease gene therapy program.
Qure’s AMT-130 faces FDA efficacy doubts after 12-month data. QURE's upside now hinges on political pressure. Read here for ...
AMT is in the business of operating cell towers. It owns more than 220,000 of them throughout the U.S. and other parts of the world, including Asia, Latin America, Europe and Africa. The company is ...
About 45 years ago, Congress enacted what's known as the alternative minimum tax (AMT), because some wealthy families were legally using so many deductions and tax breaks that they were paying no ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results